Taisho Pharma completes buy of 24.5% stake in Duoc Hau Giang Pharma
Japan’s Taisho Pharmaceutical(TYO: 4535) has completed the acquisition of 24.5% of shares of Vietnam-based Duoc Hau Giang Pharmaceutical JSC (DHG). Financial terms of the transaction were not disclosed.
Taisho Group believes that the transaction and alliance will enable the group to share its knowledge, technology, and know-how in the pharmaceutical business with DHG, resulting in an increase in DHG's sales and further growth of Taisho Group's and DHG's businesses in Asia. In addition, synergy is expected between DHG, with its strong presence in Vietnam, and Taisho Group.
Taisho Group is committed to enhancing its pharmaceutical business in Asia and striving to grow various business segments in the continuously expanding Asia market. The impact of the Transaction on the financial condition of Taisho Group is expected to be non-material.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
More on this story...
Today's issue
Company Spotlight
More Features in Pharmaceutical
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze